What's Happening?
A systematic review of seventeen rat studies has indicated that both repurposed drugs and herbal compounds improved cognitive performance in an animal model designed to mimic Alzheimer’s disease in postmenopausal women. The model involved surgically removing
ovaries to reproduce estrogen loss and injecting d-galactose to induce oxidative stress and neuronal damage. Among the repurposed drugs, escitalopram, dimethyl fumarate, telmisartan, and dapagliflozin showed promise. Two anticancer agents, lapatinib ditosylate and pazopanib, also appeared in the review, improving cognitive outcomes and reducing amyloid and tau pathology. Herbal compounds like ginsenoside Rg1, resveratrol, rosmarinic acid, tea polyphenols, scoparone, alcoholic extract of Erigeron bonariensis, and extra-virgin avocado oil also demonstrated memory-enhancing effects. However, the authors caution that the overall certainty of this evidence is extremely low due to methodological limitations in the studies.
Why It's Important?
This research is important because it explores potential new avenues for treating Alzheimer's disease, particularly in postmenopausal women, a demographic with a higher risk of developing the condition. Repurposing existing drugs could accelerate the development of treatments, as these drugs have already undergone extensive safety testing. The identification of herbal compounds with cognitive benefits also opens doors for natural product research. If these findings can be validated in more rigorous preclinical and eventually clinical studies, they could lead to novel therapeutic strategies, offering hope to millions affected by Alzheimer's. The focus on postmenopausal models addresses a critical gap in Alzheimer's research, as hormonal changes are believed to play a significant role in disease progression in women.
What's Next?
The authors emphasize the need for rigorously designed preclinical studies with larger sample sizes and transparent reporting before any clinical translation can be considered. Future research will need to address the methodological shortcomings identified in the review, such as unclear allocation concealment, lack of blinding, and inconsistent dosing regimens. While the current findings are hypothesis-generating, they suggest that escitalopram, telmisartan, dimethyl fumarate, and dapagliflozin are among the most promising repurposed candidates, and ginsenoside Rg1 and resveratrol show the most consistent herbal evidence. The next steps will involve more robust preclinical validation to confirm efficacy and safety, potentially leading to human clinical trials for the most promising compounds.
Beyond the Headlines
The exploration of repurposed drugs and herbal compounds for Alzheimer's treatment highlights a broader trend in medical research: looking beyond novel drug discovery to existing resources. This approach can be more cost-effective and time-efficient. The inclusion of anticancer agents in this review, such as lapatinib ditosylate and pazopanib, suggests potential shared biological pathways between cancer and neurodegenerative diseases, opening up new avenues for understanding disease mechanisms. Furthermore, the emphasis on postmenopausal models underscores the growing recognition of sex-specific differences in disease presentation and progression, which could lead to more personalized and effective treatments for Alzheimer's disease.
